• Predicting Major Bleeding During Extended Anticoagulation fo

  2026-07-28

  This study introduces and validates a novel clinical prediction model (CHAP) for major bleeding risk during extended anticoagulation in patients with unprovoked or weakly provoked venous thromboembolism (VTE). By comparing the CHAP model with existing risk scores, the research provides a more streamlined approach to risk estimation, potentially informing safer anticoagulation management.

• Applied Protocols for Salvianolic Acid B in Pulmonary Fibros

  2026-07-28

  Salvianolic acid B (Dan Shen Suan B) is redefining pulmonary fibrosis research by directly inhibiting LH2-driven collagen cross-linking, enabling precise modulation of extracellular matrix remodeling. This article delivers actionable protocols, optimization strategies, and troubleshooting tips for deploying this high-purity natural compound in advanced fibrotic disease models.

• Dimetridazole Disarms P. aeruginosa via Quorum Sensing Inhib

  2026-07-27

  The referenced study demonstrates that Dimetridazole, a 1,2-dimethyl-5-nitroimidazole, suppresses Pseudomonas aeruginosa virulence by targeting its quorum sensing system rather than exerting traditional bactericidal effects. These findings highlight a promising antivirulence strategy with potential to enhance antibiotic susceptibility and combat drug-resistant infections.

• Phillygenin Attenuates Diabetic Nephropathy via Inflammation

  2026-07-27

  This study demonstrates that phillygenin (PHI), a Forsythia suspensa-derived flavonoid, alleviates diabetic nephropathy (DN) by inhibiting inflammation and apoptosis in kidney cells and mouse models. Mechanistically, PHI exerts its effects through modulation of the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways, offering a promising candidate for DN therapy.

• Caffeic Acid Phenethyl Ester (CAPE): Unraveling Tumor and Ne

  2026-07-26

  Explore how Caffeic Acid Phenethyl Ester (CAPE) enables precise inhibition of NF-κB and modulation of angiogenesis, offering new experimental insights that bridge oncology and neuroinflammation research. This article provides a unique, protocol-driven perspective on leveraging CAPE in advanced disease modeling.

• FPR2/ALX Stimulation Restricts Neuroinflammation via Microgl

  2026-07-25

  The reference study demonstrates that FPR2/ALX activation with Quin-C1 reduces neuroinflammation and demyelination in a mouse model of autoimmune astrocytopathy by modulating microglia and NK cell activity through SYK-AKT signaling. These findings suggest a novel immunomodulatory strategy for diseases like NMOSD, with practical implications for dissecting neuroimmune mechanisms.

• Cytosolic DNA Drives TDP-43 Proteinopathy via Phase Separati

  2026-07-24

  This study uncovers how cytosolic DNA accumulation disrupts the homeostasis of TAR DNA-binding protein 43 (TDP-43), promoting its cytoplasmic aggregation—a hallmark of neurodegenerative diseases such as ALS. The findings highlight DNA-driven phase separation as a key mechanism underlying TDP-43 pathology and suggest new investigative angles for DNA damage and neurodegeneration research.

• DAF-2 Diacetate Illuminates NO Pathways in Soybean Symbiosis

  2026-07-24

  Translational researchers striving to extend legume nodule lifespan and boost sustainable nitrogen fixation now face a strategic inflection point: mechanistically dissecting reactive nitrogen species (RNS) in live symbiotic systems. This article unites recent breakthroughs in sulfur-mediated nodule senescence with advanced nitric oxide (NO) detection, showcasing how DAF-2 diacetate (4,5-Diaminofluorescein diacetate) from APExBIO empowers precision NO pathway study. By bridging plant biology, redox biochemistry, and live-cell imaging, we offer a roadmap for exploiting NO bioimaging probes to accelerate both fundamental discovery and translational application.

• Ranolazine (SKU A8510): Reliable Solutions in Cardiac Resear

  2026-07-23

  This article provides an evidence-based, scenario-driven guide for using Ranolazine (SKU A8510) in laboratory workflows addressing cardiac ischemia and metabolic assays. Drawing on validated best practices and comparative product insights, researchers will discover how Ranolazine from APExBIO ensures reproducibility and data integrity for cell-based experiments.

• Thrombin B Chain: Mechanistic Insights and Translational Lev

  2026-07-23

  Explore how ultra-pure Coagulation Factor II (Thrombin) B Chain Fragment reframes the experimental and translational toolkit for vascular biology, angiogenesis, and disease modeling. This article bridges molecular mechanism, workflow strategy, and clinical ambition—backed by cutting-edge literature and benchmarking against current best practices.

• RNF166 Targets Poly-ADP-Ribosylated Angiomotins in Colorecta

  2026-07-22

  This study uncovers RNF166 as a key E3 ubiquitin ligase that specifically recognizes and destabilizes poly-ADP-ribosylated angiomotins, promoting YAP activation and colorectal cancer progression. The work clarifies a previously unrecognized mechanism of Hippo pathway regulation, highlighting new therapeutic targets and presenting methodological advances applicable to protein modification research.

• N-octanoyl-L-Homoserine lactone in Cancer and Pathogenicity

  2026-07-22

  N-octanoyl-L-Homoserine lactone (C8-HSL) is redefining infection biology and cancer research by enabling precise modeling of quorum-sensing-driven pathogenicity and tumor progression. This guide delivers actionable workflows, protocol enhancements, and troubleshooting strategies for leveraging C8-HSL in advanced experimental setups.

• Modeling Breast Tumor Relapse: Proliferation Tracing in Mice

  2026-07-21

  This study introduces a dual recombinase genetic mouse model for tracing and ablating proliferating breast cancer cells, providing a robust platform to investigate mechanisms of tumor relapse. The integration of single-cell transcriptomics reveals how dormant cancer cell populations and microenvironmental shifts drive recurrence, offering new avenues for preclinical testing and targeted therapy development.

• mRNA-LNP Programming of CAR Macrophages for Peritoneal Cance

  2026-07-21

  This study presents a macrophage-targeted mRNA lipid nanoparticle platform for in situ programming of chimeric antigen receptor (CAR) macrophages, enabling robust immunotherapy against peritoneal metastasis. The approach systematically compares CAR designs, uncovers key immune mechanisms, and offers insights into overcoming tumor immunosuppression.

• MK-5108 (VX-689) Aurora-A Kinase Inhibitor: Lab-Ready Select

  2026-07-20

  This article explores how MK-5108 (VX-689) Aurora-A kinase inhibitor, highly selective (SKU A4120), addresses key laboratory challenges in cell cycle, viability, and tumor proliferation assays. Through evidence-driven Q&A scenarios, we highlight the compound’s nanomolar potency, rigorous selectivity, and experimental reliability for cancer research workflows. Practical protocol guidance and vendor comparison ensure bench scientists can confidently integrate MK-5108 (VX-689) into demanding oncology research.

15747 records 1/1050 page Next 12345 下5页 Last page